<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690337</url>
  </required_header>
  <id_info>
    <org_study_id>DS1123-A-J101</org_study_id>
    <nct_id>NCT02690337</nct_id>
  </id_info>
  <brief_title>Study of DS-1123a in Advanced Solid Tumours</brief_title>
  <official_title>Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of
      DS-1123a in Japanese subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Cycles 1, 2 : Days 1,2, 4, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Day 1 to Day 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum concentration (Tmax)</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate constant (Kel)</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve AUClast</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUCtau)</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUCinf)</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug clearance (CL)</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz)</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time (MRTinf)</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DS-1123a antibody</measure>
    <time_frame>Cycle 1: Days 1,15; Cycles 2: Day 1; Stop date, final follow-up date</time_frame>
    <description>DS-1123a antibody on Cycle 1: Days 1,15; Cycles 2 and on: Day 1, Stop date, final follow-up date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cytokines expression</measure>
    <time_frame>Cycle 1: Days 1, 2, 15, 16; Cycle 2: Days 1, 2</time_frame>
    <description>Change in DS-1123a biomarkers Cytokines expression on Cycle 1: Days 1, 2, 15, 16; Cycle 2: Days 1, 2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Advanced Solid Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>DS-1123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study will follow a modified Continual Reassessment Method (mCRM) + Escalation with Overdose Control (EWOC),design with a starting intravenous (IV) dose of 0.1 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-1123</intervention_name>
    <description>starting intravenous (IV) dose of 0.1 mg/kg.</description>
    <arm_group_label>DS-1123</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid tumor that is refractory to standard treatment, or for which no
             standard treatment is available.

          -  Eastern Cooperative Oncology Group performance status (PS) of 0 or 1.

        Exclusion Criteria:

          -  Have any of the following concomitant disease or had the history of having following
             disease within 6 months before enrollment:

             • Cardiac failure (NYHA ≥ ClassIII), myocardial infarction, cerebral infarction,
             unstable angina, arrhythmia requiring treatment, coronary-artery/peripheral artery
             bypass surgery, cerebrovascular disease, pulmonary thromboembolism, deep-vein
             thrombosis or clinically severe thromboembolic event, or clinically severe pulmonary
             disease (eg, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, drug
             induced pneumonia),

          -  Severe or uncontrolled concomitant disease.

          -  Clinically active brain metastases defined as symptomatic or requiring treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid malignant tumors</keyword>
  <keyword>phase 1</keyword>
  <keyword>oncology</keyword>
  <keyword>refractory</keyword>
  <keyword>no standard treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

